Download presentation
Presentation is loading. Please wait.
Published byὙπατος Πολίτης Modified over 5 years ago
1
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: A randomized controlled trial Renate Koppensteiner, MD, Silviana Spring, MD, Béatrice R. Amann-Vesti, MD, Thomas Meier, MD, Thomas Pfammatter, MD, Valentin Rousson, PhD, Martin Banyai, MD, Bernd van der Loo, MD Journal of Vascular Surgery Volume 44, Issue 6, Pages (December 2006) DOI: /j.jvs Copyright © 2006 The Society for Vascular Surgery Terms and Conditions
2
Fig 1 Flow of patients through each stage of the study.
Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions
3
Fig 2 A, Kaplan-Meier curve for freedom from restenosis/reocclusion by treatment group (total). B, Kaplan-Meier curve for freedom from restenosis/reocclusion in patients with claudication by treatment group. C, Kaplan-Meier curve for freedom from restenosis/reocclusion in patients with critical limb ischemia by treatment group. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions
4
Fig 3 A, Peak velocity ratio (Vr) after femoropopliteal percutaneous transluminal angioplasty (PTA) in the total of patients by treatment group. B, Peak velocity ratio (Vr) after femoropopliteal PTA in patients with critical limb ischemia by treatment group. Boxes show medians (25th to 75th percentile); the blue dots represent all observations <10th or >90th percentile, respectively. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.